Daratumumab Plus Standard Therapy for Multiple Myeloma

<!DOCTYPE html> <html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta charset="utf-8" /> <script>window.CDEConfig = { "exitDisclaimerHref":{ "en":"\/policies\/linking", "es":"\/espanol\/politicas\/enlaces" }, "showFloatingDelighters":true, "environmentConfig":{ }, "glossaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/" }, "drugDictionaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/" }, "ctsConfig":{ "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2", "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print", "zipConversionEndpoint":"\/cts_api\/zip_code_lookup" }, "r4rConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1" }, "general":{ "apiServer":"https:\/\/webapis.cancer.gov", "mediaServer":"https:\/\/nci-media.cancer.gov" }, "sitewideSearchConfig":{ "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/", "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/" }, "chartData": { "factBook": { "baseUrl": "\/about-nci\/budget\/fact-book", "dataType": "json" } } };</script> <script id="ncids-nav-info">window.ncidsNavInfo = { nav: { id: "860258", menu_type: "section-nav"}, item_id: 860258};</script> <meta name="description" content="Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying." /> <link rel="canonical" href="https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd" /> <meta http-equiv="content-language" content="en" /> <meta name="robots" content="index" /> <meta property="og:type" content="Website" /> <meta property="og:url" content="https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd" /> <meta property="og:title" content="Daratumumab Plus Standard Therapy for Multiple Myeloma" /> <meta property="og:description" content="Adding daratumumab (Darzalex) to standard VRD treatment helped people with newly diagnosed multiple myeloma live longer without their cancer getting worse or dying." /> <meta property="og:image" content="https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_social_media/public/cgov_image/media_image/2024-01/cancer-cell-antibody.jpg" /> <meta name="cgdp.domain" content="cgov" /> <meta name="cgdp.template" content="default" /> <meta name="dcterms.subject" content="News and Events" /> <meta name="dcterms.type" content="cgvBlogPost" /> <meta name="dcterms.coverage" content="nciglobal,ncienterprise" /> <meta name="dcterms.isPartOf" content="CancerCurrents" /> <meta name="dcterms.isReferencedBy" content="event1,event53" /> <meta name="dcterms.issued" content="01/19/2024 - 07:00" /> <meta name="twitter:card" content="summary" /> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico" sizes="32x32"/> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.svg" type="image/svg+xml"/> <link rel="apple-touch-icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png"/> <link rel="manifest" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/site.webmanifest"/> <meta name="x-no-op" content="none" /> <meta name="Generator" content="Drupal 10 (https://www.drupal.org)" /> <meta name="MobileOptimized" content="width" /> <meta name="HandheldFriendly" content="true" /> <meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /> <script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js" async="async"></script> <script type="application/ld+json">{ "@context": "https://schema.org", "@graph": [ { "@type": "WebSite", "name": "National Cancer Institute (.gov)", "url": "https://www.cancer.gov" } ] }</script> <link rel="alternate" hreflang="en" href="https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd" /> <link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog/2024/darzalex-mas-tratamiento-estandar-para-mieloma-multiple" /> <title>Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI</title> <link rel="preconnect" href="https://static.cancer.gov" /> <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&display=swap" rel="stylesheet"> <meta name="apple-mobile-web-app-title" content="Cancer.gov" /> <meta name="application-name" content="Cancer.gov" /> <link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_dpKR6GJ0SAlxAov6RWJNbTUa0NBSCaYTn6_G1M5wkqA.css?delta=0&language=en&theme=ncids_trans&include=eJwFwUEKwCAMBMAPCXmSJLqUQI3F3Yu_7wwvhWXhREMpdTtWYNrwT7mr1cjJruNFi3c__AH3vRO8" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?smm34w" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/blogs.css?smm34w" /> </head> <body class="has-translated-content"> <a href="#main-content" class="usa-skipnav"> Skip to main content </a> <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas> <section id="usa-banner" class="usa-banner" aria-label="Official government website"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="usa-banner__header-text"> An official website of the United States government </div> <a href="/espanol/noticias/temas-y-relatos-blog/2024/darzalex-mas-tratamiento-estandar-para-mieloma-multiple" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es">Español</a> </div> </header> </section> <header id="nci-header" class="nci-header nci-header--megamenu" data-base-path="/"> <div class="nci-header__navbar"> <div class="nci-logo" id="extended-mega-logo"> <a href="/" aria-label="National Cancer Institute Home Page"> <picture><source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /> <img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /> </picture> </a> </div> <div class="nci-header-nav__secondary"> <button class="usa-button nci-header-mobilenav__open-btn">Menu</button> <form class="nci-header-search" method="get" action="/search/results" role="search"> <label class="usa-sr-only" for="nci-header-search__field"> Search </label> <input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword" data-autosuggest-collection="cgov"/> <button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"> <span class="nci-header-search__label" aria-hidden="true">Search</span> <svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/> </svg> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="nci-header-nav"> <div class="nci-header-nav__inner"> <ul class="nci-header-nav__primary"> <li class="nci-header-nav__primary-item"> <a href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"> <span>About Cancer</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/types" class="nci-header-nav__primary-link" data-menu-id="11868"> <span>Cancer Types</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"> <span>Research</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"> <span>Grants & Training</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/news-events" class="nci-header-nav__primary-link usa-current" data-menu-id="12664"> <span>News & Events</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"> <span>About NCI</span> </a> </li> </ul> </div> </nav> </header> <div class="grid-container"> <div class="grid-row flex-no-wrap"> <div class="grid-col-10"> <nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"> <ol class="usa-breadcrumb__list"> <li class="usa-breadcrumb__list-item"> <a href="/" class="usa-breadcrumb__link"> <span>Home</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events" class="usa-breadcrumb__link"> <span>News & Events</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events/cancer-currents-blog" class="usa-breadcrumb__link"> <span>Cancer Currents Blog</span> </a> </li> <li class="usa-breadcrumb__list-item usa-current" aria-current="page"> <span>Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma</span> </li> </ol> </nav> </div> <section class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> </div> <div id="page" class="grid-container"> <div class="grid-row grid-gap"> <div data-drupal-messages-fallback class="hidden"></div> <div class="cgdpl desktop:grid-col-9"> <main id="main-content" class="contentzone"> <div>  <article> <div class="resize-content"> <h1> Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma </h1> <div id="nvcgSubTitle"> <div class="subscribeRSS"> <a class="blogRSS" href="https://public.govdelivery.com/accounts/USNIHNCI/subscriber/new?topic_id=USNIHNCI_38"><span>Subscribe</span></a> </div> </div> <div id="cgvBody" class="cgvblogpost"> <p class="blog-post-publishing-info"> <time datetime="2024-01-19T12:00:00Z">January 19, 2024</time>, by Nadia Jaber </p> <div data-entity-embed-display="view_mode:media.image_display_article_medium" class="embedded-entity align-right"> <figure class="image-medium centered-set"> <div class="centered-element"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_article/public/cgov_image/media_image/2024-01/cancer-cell-antibody.jpg?h=24c758e7&itok=GP2wchM3" width="970" height="613" alt="An illustration of antibodies on the surface of and floating around cancer cells " /> </div> <figcaption> <div class="caption-container no-resize"> <p>Daratumumab (pink) is an antibody drug that binds to specific proteins on multiple myeloma cells (blue). It kills cancer cells directly and also recruits immune cells that kill cancer cells.</p> <div class="image-photo-credit">Credit: iStock</div> </div> </figcaption> </figure> </div> <p style="margin-bottom:11px">A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="46bba29e-e684-483d-a5ec-c3881fd147e8" href="/about-cancer/treatment/drugs/daratumumab">daratumumab (Darzalex)</a> to a standard treatment regimen was more effective than that standard regimen on its own.</p> <p>Trial participants <a href="https://pubmed.ncbi.nlm.nih.gov/38084760/">treated with daratumumab lived substantially longer</a> without their cancer getting worse or dying than those who received the standard treatment only.</p> <p>After a <a class="definition" data-glossary-id="CDR0000044941" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044941&version=Patient&language=en">median</a> of 4 years, 84% of those who received daratumumab plus the standard treatment and 68% of patients who received the standard treatment—which included <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="6f0ba82e-64d3-4be5-a83a-25d97c41217c" href="/about-cancer/treatment/drugs/bortezomib">bortezomib (Velcade)</a>, <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="91fe649f-dee9-4e41-8cfd-6c8ea63ee35e" href="/about-cancer/treatment/drugs/lenalidomide">lenalidomide (Revlimid)</a>, and <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="76557340-c0e6-4ffa-a2f6-ff8d2f02b81f" href="/about-cancer/treatment/drugs/dexamethasone">dexamethasone</a>—were alive and free of cancer progression.</p> <p>That is “a striking benefit in <a class="definition" data-glossary-id="CDR0000044782" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044782&version=Patient&language=en">progression-free survival</a>,” said C. Ola Landgren, M.D., Ph.D., director of the Sylvester Myeloma Institute at the University of Miami, who was not involved in the trial.</p> <p>People treated with daratumumab were also more likely to have no detectable signs of cancer (what’s called <a class="definition" data-glossary-id="CDR0000797386" href="/Common/PopUps/popDefinition.aspx?id=CDR0000797386&version=Patient&language=en">minimal residual disease</a>, or MRD) after treatment. Findings from the trial, called PERSEUS, were published in the <em>New England Journal of Medicine</em> and presented at the annual meeting of the American Society of Hematology on December 12. </p> <p>In 2020, a small clinical trial found that adding daratumumab to this standard treatment regimen <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7441167/">resulted in substantial benefits</a> for people with newly diagnosed multiple myeloma.</p> <p>While some physicians started prescribing this drug combination right away, others have been holding out for stronger data, explained Surbhi Sidana, M.D., a hematologist–oncologist at Stanford University.</p> <p>Results from the new trial provide “very important confirmatory data that settles this issue for people who were holding out on progression-free survival [data] from a phase 3 study. For people who were waiting, this changes their practice,” Dr. Sidana said at the annual meeting of the American Society of Hematology.</p> <p>While daratumumab is approved by the Food and Drug Administration for use with other drug combinations, it is not yet approved for use with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma.</p> <h2>Intravenous or subcutaneous daratumumab</h2> <div data-embed-button="cgov_featured_content_button" data-entity-embed-display="view_mode:node.embedded_feature_card" data-entity-type="node" data-entity-uuid="ebd80823-9c31-495c-ade0-6595201e75e2" data-langcode="en" data-entity-embed-display-settings="[]" class="embedded-entity align-right"> <div class="feature-card"> <a href="/news-events/cancer-currents-blog/2023/motixafortide-multiple-myeloma-stem-cell-transplant"> <div class="image-hover"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_featured/public/cgov_image/media_image/2023-05/stem%20cell%20collection.PNG?h=3e98fe83&itok=ale7mMiR" width="425" height="318" alt="An illustration of a young man undergoing an apheresis procedure for stem cell collection."> </div> <h3>Experimental Drug May Aid Stem Cell Transplants for Multiple Myeloma</h3> <p>Motixafortide increased the amount of stem cells in the blood for use in transplants.</p> </a> </div> </div> <p>For many younger people who have just been diagnosed with multiple myeloma, the initial treatment is a multistep process that includes a cocktail of drugs and a <a class="definition" data-glossary-id="CDR0000046695" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046695&version=Patient&language=en">stem cell transplant</a>.</p> <p>This approach has been in place for more than 10 years, noted Pieter Sonneveld, M.D., Ph.D., of Erasmus MC Cancer Institute in the Netherlands and leader of the PERSEUS trial.</p> <p>Over the past decade, researchers have been tweaking the drug cocktail, swapping out or adding in new medicines to see if different combinations better eradicate the cancer and delay its return.</p> <p>“With the PERSEUS study, we tried to improve on the standard treatment by adding daratumumab,” Dr. Sonneveld said.</p> <p>Daratumumab is a targeted cancer drug that kills multiple myeloma cells and also recruits immune cells to help kill cancer cells. It can be infused through a vein (intravenous) or injected under the skin (subcutaneous).</p> <p>Whereas both delivery routes have similar effects on multiple myeloma, subcutaneous injections of daratumumab cause fewer adverse reactions and are far less of a time burden for patients. Intravenous infusions are given over the course of a few hours, while subcutaneous injections take only a few minutes, Dr. Landgren explained.</p> <p>In the 2020 trial, daratumumab was given through intravenous infusions. But since then, subcutaneous injections have been preferred, Dr. Landgren said. In the PERSEUS trial, the researchers used subcutaneous daratumumab.</p> <h2>The PERSEUS trial</h2> <p>More than 700 people with newly diagnosed multiple myeloma participated in the trial, which took place across 14 countries in Europe and Australia and was partially funded by Janssen, the company that makes daratumumab. </p> <p>All participants were eligible for a stem cell transplant, which typically means they are younger and have better overall health. All participants were randomly assigned to receive the following standard regimen with or without subcutaneous daratumumab:</p> <ul> <li><a class="definition" data-glossary-id="CDR0000045736" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045736&version=Patient&language=en">Induction therapy</a> with bortezomib, lenalidomide, and dexamethasone</li> <li>Stem cell transplant</li> <li><a class="definition" data-glossary-id="CDR0000045654" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045654&version=Patient&language=en">Consolidation therapy</a> with bortezomib, lenalidomide, and dexamethasone</li> <li><a class="definition" data-glossary-id="CDR0000045768" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045768&version=Patient&language=en">Maintenance therapy</a> with lenalidomide</li> </ul> <p>Patients in the daratumumab group received the drug as part of induction, consolidation, and maintenance therapy.</p> <p>Investigators tracked patients’ outcomes using multiple measures for a median of nearly 4 years. For all measures, the standard regimen plus daratumumab was more effective than the standard regimen alone.</p> <p>For example, people in the daratumumab group had higher rates of deep responses, such as complete or stringent <a class="definition" data-glossary-id="CDR0000045652" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045652&version=Patient&language=en">complete responses</a> (no signs of cancer using classic blood and other tests), and MRD negativity (no signs of cancer using highly sensitive DNA tests).</p> <table border="1" cellpadding="1" cellspacing="1"> <tbody> <tr> <td> </td> <td><strong>Daratumumab plus<br> standard treatment</strong></td> <td><strong>Standard treatment</strong></td> </tr> <tr> <td>Progression-free survival at 4 years</td> <td>84%</td> <td>68%</td> </tr> <tr> <td>Complete response or stringent complete response</td> <td>88%</td> <td>70%</td> </tr> <tr> <td>MRD negative</td> <td>75%</td> <td>48%</td> </tr> <tr> <td>MRD negative for at least 1 year</td> <td>65%</td> <td>30%</td> </tr> </tbody> </table> <p style="margin-bottom:11px">People in the daratumumab group who stayed MRD negative for at least a year were able to stop taking daratumumab as maintenance therapy and remained cancer free. That’s important, Dr. Sonneveld said, because taking fewer drugs long-term for maintenance therapy often translates to a better well-being and quality of life.</p> <p>Adding daratumumab to the standard treatment resulted in a nearly 60% drop in the risk of cancer progression or death (<a class="definition" data-glossary-id="CDR0000618612" href="/Common/PopUps/popDefinition.aspx?id=CDR0000618612&version=Patient&language=en">hazard ratio</a> of 0.42), the researchers determined.</p> <p>The magnitude of that change is “unprecedented in these kinds of phase 3 trials [for] multiple myeloma,” Dr. Sonneveld said.</p> <p>Participants have not been followed long enough to see if daratumumab improved how long they live overall. The trial is ongoing and overall survival will continue to be tracked, the investigators noted.</p> <div data-embed-button="cgov_image_button" data-entity-embed-display="view_mode:media.image_display_article_medium" data-entity-embed-display-settings="[]" data-entity-type="media" data-entity-uuid="ee37dffe-96af-4b32-a89b-705573d82134" data-langcode="en" class="embedded-entity align-right"> <figure class="image-medium centered-set"> <div class="centered-element"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_article/public/cgov_image/media_image/2024-01/Desktop%20copy.png?itok=0TvTjDi0" width="970" height="970" alt="Graph depicting the amount of cancer left at various stages of response to treatment."> <a href="/sites/g/files/xnrzdm211/files/styles/cgov_enlarged/public/cgov_image/media_image/2024-01/Desktop%20copy.png?itok=zKfTsQah" target="_blank" class="article-image-enlarge no-resize">Enlarge</a> </div> </figure> </div> <h2>Side effects of adding daratumumab</h2> <p>Side effects like infections and a lower-than-normal number of white blood cells (neutropenia) or platelets (thrombocytopenia) were more common among patients in the daratumumab group.</p> <p>A higher percentage of patients in the daratumumab group than the standard treatment group experienced a serious side effect (57% versus 49%). However, fewer patients in the daratumumab group stopped treatment due to side effects (9% versus 22%).</p> <p>Eleven percent of patients in the daratumumab group and 7% in the standard treatment group developed a second type of cancer—meaning, cancer that was not multiple myeloma. Slightly more patients in the daratumumab group than the standard treatment group were able to receive a stem cell transplant (90% versus 87%). A serious side effect of stem cell transplantation is the risk of additional cancers.</p> <p>A similar percentage of patients in both groups died from complications related to side effects: 4% in the daratumumab group and 5% in the standard treatment group.</p> <h2>One among several treatment options</h2> <div data-embed-button="cgov_featured_content_button" data-entity-embed-display="view_mode:node.embedded_feature_card" data-entity-type="node" data-entity-uuid="8fd956a0-075f-4238-b3a5-963165833e23" data-langcode="en" data-entity-embed-display-settings="[]" class="embedded-entity align-right"> <div class="feature-card"> <a href="/news-events/cancer-currents-blog/2017/three-drug-combination-myeloma"> <div class="image-hover"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_featured/public/cgov_image/media_image/100/200/8/files/proteasome-nigms-article.jpg?h=e889c29c&itok=gdxUjKhz" width="425" height="319" alt> </div> <h3>Drug Triplet Extends Survival for Multiple Myeloma</h3> <p>Combination should be adopted as standard of care for some patients, experts say.</p> </a> </div> </div> <p>Findings from the PERSEUS trial will likely add one more option to the treatments available for people with multiple myeloma, Dr. Landgren said.</p> <p>Daratumumab is already FDA approved to be used with other drug combinations for newly diagnosed multiple myeloma. One such combination includes bortezomib, dexamethasone, and <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="73a90d6b-c540-457e-85dd-695e5459fc9f" href="/about-cancer/treatment/drugs/thalidomide">thalidomide (Thalomid)</a>.</p> <p>And other options may be coming down the line. The <a href="https://www.cancer.gov/clinicaltrials/NCT04268498">ongoing ADVANCE study</a> is comparing daratumumab plus another three-drug combination (<a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="74536447-a7c6-4eef-ac8b-ff0460a9a3ce" href="/about-cancer/treatment/drugs/carfilzomib">carfilzomib [Kyprolis]</a>, lenalidomide, and dexamethasone) to the three-drug combination alone in people with newly diagnosed multiple myeloma. </p> <p>And another clinical trial is investigating the effects of adding <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="53fcf2fa-6ff5-4d9e-b1cc-faf926bfe621" href="/about-cancer/treatment/drugs/isatuximab-irfc">isatuximab (Sarclisa)</a>—which targets the same protein as daratumumab—to carfilzomib, lenalidomide, and dexamethasone. Preliminary results of the trial, also presented at the American Society of Hematology annual meeting, <a href="https://ashpublications.org/blood/article/142/Supplement%201/4/503120/Results-of-the-Phase-III-Randomized-Iskia-Trial">suggest that the combination is promising</a> for newly diagnosed multiple myeloma.</p> <p>What’s currently unclear is whether patients need to take daratumumab during all pre- and post-transplant phases of therapy to reap its benefits, Dr. Landgren said.</p> <p>One ongoing clinical trial is exploring that question. In this trial, daratumumab was added to bortezomib, thalidomide, and dexamethasone. Early results from the trial suggest that <a href="https://pubmed.ncbi.nlm.nih.gov/34529931/">daratumumab may be most effective</a> when added to all three phases of the standard treatment regimen.</p> </div> </div> <footer class="article-footer"> <div id='cgov-blog-post-pagination' class='clearfix'> <div class='blog-post-older'> <a href="/news-events/cancer-currents-blog/2024/preventive-gastrectomy-long-term-consequences">< Older Post</a> <p><i>For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting Consequences</i></p> </div> <div class='blog-post-newer'> <a href="/news-events/cancer-currents-blog/2024/breast-cancer-skip-lymph-node-radiation">Newer Post ></a> <p><i>Can Some People with Breast Cancer Safely Skip Lymph Node Radiation?</i></p> </div> </div> <div id="nvcgSlPublicUse"> <div class="slot-item only-SI"> <div class="public-use"> <div id="block-ncids-trans-public-use"> <p><em>If you would like to reproduce some or all of this content, see <a href="/policies/copyright-reuse">Reuse of NCI Information</a> for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma was originally published by the National Cancer Institute.”</em></p> </div> </div> </div> </div> </footer> </article>  </div> </main> </div>   <div class="cgdpl desktop:grid-col-3"> <div id="nvcgSlListBlogRTRail" class="right-rail"> <div class="slot-item"> <div class="managed list with-date"> <h2 id="Featured+Posts">Featured Posts</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/medical-cannabis-oncologists-patients-communication">Oncologists Struggle to Answer Questions About Medical Cannabis</a> <div class="byline"> <p> October 16, 2024, by Carmen Phillips </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/mammogram-false-positives-affect-future-screening">Mammogram False Positives Can Affect Future Screening Behavior</a> <div class="byline"> <p> October 4, 2024, by Edward Winstead </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/ancient-retrovirus-dna-ltr10-cancer">DNA From an Ancient Virus Helps Many Cancers Grow</a> <div class="byline"> <p> September 6, 2024, by Nadia Jaber </p> </div> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="managed list without-date"> <h2 id="Categories">Categories</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=biology">Biology of Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=cancer-risk">Cancer Risk</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=childhood-cancer">Childhood Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=clinical-trial-results">Clinical Trial Results</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=disparities">Disparities</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=fda-approvals">FDA Approvals</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=global-health">Global Health</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=leadership-expert-views">Leadership & Expert Views</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prevention">Prevention</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prognosis">Prognosis</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=screening-early-detection">Screening & Early Detection</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=survivorship-supportive-care">Survivorship & Supportive Care</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=technology">Technology</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=treatment">Treatment</a> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="desktop"> <div id="blog-archive-accordion"> <h2 id="archive" class="blog-archive-header"> Archive </h2> <div id="blog-archive-accordion-year"> <h3> 2024 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=11"> November </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=09"> September </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=07"> July </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=06"> June </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=04"> April </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=02"> February </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=01"> January </a> (6) </li> </ul> <h3> 2023 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=11"> November </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=09"> September </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=01"> January </a> (6) </li> </ul> <h3> 2022 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=10"> October </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=03"> March </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=01"> January </a> (6) </li> </ul> <h3> 2021 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=11"> November </a> (4) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=09"> September </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=06"> June </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=04"> April </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=02"> February </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=01"> January </a> (6) </li> </ul> <h3> 2020 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=05"> May </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=01"> January </a> (7) </li> </ul> <h3> 2019 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=12"> December </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=09"> September </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=07"> July </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=06"> June </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=03"> March </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=02"> February </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=01"> January </a> (6) </li> </ul> <h3> 2018 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=12"> December </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=11"> November </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=10"> October </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=09"> September </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=06"> June </a> (12) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=03"> March </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=02"> February </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=01"> January </a> (10) </li> </ul> </div> </div> </div> </div> </div> </div>  </div> <section class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog/2024/multiple-myeloma-darzalex-plus-vrd %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> <div id="block-ncidsfooterenglish"> <footer class="usa-footer usa-footer--nci-big" id="nci-footer" aria-label="Footer" > <div class="grid-container usa-footer__return-to-top"> <a href="#top" aria-label="Back To Top"><span>Back To Top</span></a> </div> <div class="usa-footer__primary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="tablet:grid-col-8"> <nav class="usa-footer__nav" aria-label="Footer navigation"> <div class="grid-row grid-gap-4"> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">About</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/about-website">About This Website</a> </li> <li class="usa-footer__secondary-link"> <a href="/espanol">en Español</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/copyright-reuse">Reuse & Copyright</a> </li> <li class="usa-footer__secondary-link"> <a href="/social-media">Social Media</a> </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Resources</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/contact">Contact Us</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications">Publications</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications/dictionaries/cancer-terms" >Dictionary of Cancer Terms</a > </li> <li class="usa-footer__secondary-link"> <a href="/research/participate/clinical-trials-search" >Find a Clinical Trial</a > </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Policies</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/policies/accessibility">Accessibility</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/foia">FOIA</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/privacy-security" >Privacy & Security</a > </li> <li class="usa-footer__secondary-link"> <a href="/policies/disclaimer">Disclaimers</a> </li> <li class="usa-footer__secondary-link"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure</a > </li> </ul> </section> </div> </div> </nav> </div> <div class="tablet:grid-col-4"> <div class="usa-sign-up"> <div class="usa-sign-up__heading">Sign up for email updates</div> <form action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify" aria-label="Footer subscribe" class="usa-form" accept-charset="UTF-8" method="post" novalidate target="_blank" id="signup" > <input type="hidden" name="category_id" id="category_id" value="" /> <div class="usa-form-group"> <label class="usa-label" for="email"> Enter your email address </label> <input class="usa-input width-full" id="email" name="email" type="email" value="" /> </div> <button class="usa-button usa-button--accent-warm" type="submit"> Sign up </button> </form> </div> </div> </div> </div> </div> <div class="usa-footer__secondary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="usa-footer__logo grid-row desktop:grid-col-5"> <div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"> <p class="usa-footer__logo-heading"> <span class="logo__agency-name">National Cancer Institute </span> <span class="logo__parent-organization" >at the National Institutes of Health</span > </p> </div> </div> <div class="usa-footer__contact-links mobile-lg:grid-col-7"> <div class="usa-footer__contact-heading">Contact Us</div> <div class="usa-footer__address"> <div class="usa-footer__contact-info grid-row grid-gap"> <div class="tablet:grid-col-auto"> <a href="https://livehelp.cancer.gov/">Live Chat</a> </div> <div class="tablet:grid-col-auto"> <a href="tel:1-800-4-CANCER">1-800-4-CANCER</a> </div> <div class="tablet:grid-col-auto"> <a href="mailto:NCIinfo@nih.gov">NCIinfo@nih.gov</a> </div> <div class="tablet:grid-col-auto"> <a class="no-exit-notification" href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I" target="_blank" >Site Feedback</a > </div> </div> </div> </div> </div> <div class="grid-row grid-gap"> <div class="usa-footer__social-links desktop:grid-col-5"> <div class="usa-footer__social-heading">Follow us</div> <div class="grid-row grid-gap-1 nci-big__social"> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.facebook.com/cancer.gov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-labelledby="facebook-title" > <title id="facebook-title">Facebook</title> <rect fill="none" height="24" width="24" /> <path d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://twitter.com/thenci" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="x-title" > <title id="x-title">Follow on X</title> <path d="M12 22c5.5 0 10-4.5 10-10S17.5 2 12 2 2 6.5 2 12s4.5 10 10 10zm5.2-15.6L13.3 11l4.3 6.2h-3.1L11.6 13 8 17.2h-.9l4.1-4.8-4.1-6h3.1l2.7 3.9 3.4-3.9h.9zm-5.6 5.4.4.6 2.8 4h1.4l-3.5-5-.4-.6-2.6-3.7H8.3l3.3 4.7z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.instagram.com/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="instagram-title" > <title id="instagram-title">Instagram</title> <g id="Instagram"> <path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z" /> <path d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.youtube.com/NCIgov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="youtube-title" > <title id="youtube-title">Youtube</title> <g id="YouTube"> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z" /> <polygon points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.linkedin.com/company/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="linkedin-title" > <title id="linkedin-title">Linkedin</title> <g id="final"> <path d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344 C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999 s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192 c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z" /> </g> </svg> </a> </div> </div> </div> <div class="usa-footer__contact-links desktop:grid-col-7"> <div class="usa-footer__address height-full"> <div class="usa-footer__contact-info grid-row grid-gap height-full"> <address> <a href="https://www.hhs.gov/" >U.S. Department of Health and Human Services </a> <a href="https://www.nih.gov/" >National Institutes of Health </a> <a href="https://www.cancer.gov/">National Cancer Institute </a> <a href="https://usa.gov/">USA.gov</a> </address> </div> </div> </div> </div> </div> </div> </footer> </div> </div> <script src="/sites/g/files/xnrzdm211/files/js/js_qW3TLjdEty3QtOepUCSY4uh6BQEGkRIL3qUMnp3WXG4.js?scope=footer&delta=0&language=en&theme=ncids_trans&include=eJwFwUEKwCAMBMAPCXmSJLqUQI3F3Yu_7wwvhWXhREMpdTtWYNrwT7mr1cjJruNFi3c__AH3vRO8"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?smm34w"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/blogs.js?smm34w"></script> </body> </html>

CINXE.COM

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI